Vivos Therapeutics (VVOS) Competitors $4.79 -0.33 (-6.45%) (As of 12:22 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VVOS vs. LNSR, FONR, GUTS, MGRM, EDAP, NSPR, VANI, MLSS, HYPR, and APYXShould you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include LENSAR (LNSR), FONAR (FONR), Fractyl Health (GUTS), Monogram Orthopaedics (MGRM), Edap Tms (EDAP), InspireMD (NSPR), Vivani Medical (VANI), Milestone Scientific (MLSS), Hyperfine (HYPR), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry. Vivos Therapeutics vs. LENSAR FONAR Fractyl Health Monogram Orthopaedics Edap Tms InspireMD Vivani Medical Milestone Scientific Hyperfine Apyx Medical Vivos Therapeutics (NASDAQ:VVOS) and LENSAR (NASDAQ:LNSR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends. Does the media prefer VVOS or LNSR? In the previous week, Vivos Therapeutics had 2 more articles in the media than LENSAR. MarketBeat recorded 3 mentions for Vivos Therapeutics and 1 mentions for LENSAR. Vivos Therapeutics' average media sentiment score of 0.65 beat LENSAR's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LENSAR 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in VVOS or LNSR? 26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 40.2% of LENSAR shares are held by institutional investors. 3.0% of Vivos Therapeutics shares are held by company insiders. Comparatively, 38.5% of LENSAR shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, VVOS or LNSR? Vivos Therapeutics has a beta of 7.67, suggesting that its stock price is 667% more volatile than the S&P 500. Comparatively, LENSAR has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Which has better earnings and valuation, VVOS or LNSR? Vivos Therapeutics has higher earnings, but lower revenue than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivos Therapeutics$14.58M1.59-$13.58M-$5.68-0.84LENSAR$42.16M2.36-$14.38M-$1.46-5.88 Does the MarketBeat Community favor VVOS or LNSR? Vivos Therapeutics received 10 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 57.69% of users gave Vivos Therapeutics an outperform vote while only 38.46% of users gave LENSAR an outperform vote. CompanyUnderperformOutperformVivos TherapeuticsOutperform Votes1557.69% Underperform Votes1142.31% LENSAROutperform Votes538.46% Underperform Votes861.54% Do analysts rate VVOS or LNSR? Vivos Therapeutics currently has a consensus price target of $6.30, suggesting a potential upside of 31.52%. LENSAR has a consensus price target of $8.00, suggesting a potential downside of 6.76%. Given Vivos Therapeutics' higher probable upside, equities research analysts clearly believe Vivos Therapeutics is more favorable than LENSAR.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00LENSAR 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VVOS or LNSR more profitable? LENSAR has a net margin of -34.03% compared to Vivos Therapeutics' net margin of -86.19%. LENSAR's return on equity of -49.02% beat Vivos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vivos Therapeutics-86.19% -335.04% -93.58% LENSAR -34.03%-49.02%-21.12% SummaryVivos Therapeutics beats LENSAR on 9 of the 17 factors compared between the two stocks. Ad Prosper Trading AcademyA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayClick HERE to access this powerful AI Trading System Get Vivos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VVOS vs. The Competition Export to ExcelMetricVivos TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.16M$4.34B$5.18B$9.21BDividend YieldN/A44.59%5.12%4.30%P/E Ratio-0.8424.8987.6517.17Price / Sales1.5952.631,165.15121.16Price / CashN/A43.4043.2337.84Price / Book21.777.084.794.79Net Income-$13.58M$13.64M$120.46M$225.43M7 Day Performance-2.24%0.65%-0.97%-0.12%1 Month Performance49.69%-0.50%15.25%1.56%1 Year Performance-57.72%39.04%29.71%16.07% Vivos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VVOSVivos Therapeutics1.6782 of 5 stars$4.79-6.4%$6.30+31.5%-54.8%$23.16M$14.58M-0.84160News CoverageGap DownLNSRLENSAR0.5909 of 5 stars$8.37+8.7%$8.00-4.4%+173.7%$97.22M$48.87M-5.73110High Trading VolumeFONRFONARN/A$14.98-1.1%N/A-24.7%$94.79M$102.01M10.70480GUTSFractyl Health0.9108 of 5 stars$1.90+5.9%$22.00+1,060.9%N/A$91.15M$97,000.00-0.16102MGRMMonogram Orthopaedics3.261 of 5 stars$2.51-2.7%$4.00+59.4%-20.6%$86.12M$364,999.00-5.3428EDAPEdap Tms3.3037 of 5 stars$2.24+2.3%$19.00+748.2%-55.7%$83.11M$63.41M-3.45307NSPRInspireMD2.2159 of 5 stars$2.93-2.3%$4.75+62.1%+37.2%$76.43M$6.82M-3.9150Gap DownVANIVivani Medical2.8671 of 5 stars$1.17-0.8%$3.00+156.4%+3.5%$69.31MN/A-2.6020MLSSMilestone Scientific1.9756 of 5 stars$0.87-5.8%$1.25+43.5%+46.3%$67.87M$8.88M-12.4530HYPRHyperfine2.2852 of 5 stars$0.86-2.5%$1.60+85.3%-21.5%$62.98M$13.26M-1.51190APYXApyx Medical1.6913 of 5 stars$1.65+5.1%N/A-34.4%$62.11M$48.54M-1.99270Gap Up Related Companies and Tools Related Companies LENSAR Competitors FONAR Competitors Fractyl Health Competitors Monogram Orthopaedics Competitors Edap Tms Competitors InspireMD Competitors Vivani Medical Competitors Milestone Scientific Competitors Hyperfine Competitors Apyx Medical Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VVOS) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredWall St. Icon: “If you wait on this, it will already be too late”If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vivos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vivos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VVOS Stock Alerts